Most cited papers from Breast Cancer Trials

Breast Cancer Trials

What are the most cited papers from Breast Cancer Trials?

The most cited paper from Breast Cancer Trials is "Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011" (Aron Goldhirsch, W. C. Wood, Alan Stuart Coates et al., 2011), with 3,932 citations. Next come "Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013" (3,776) and "Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial" (2,067).

Published TypeFieldAccessAuthorsCitations

Showing 50 of 60 papers. Every paper with more than 62 citations is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011 Aron Goldhirsch, W. C. Wood, Alan Stuart Coates et al. · Annals of Oncology Open access	28 Jun 2011	3,932
2	Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 Aron Goldhirsch et al. · Annals of Oncology Open access	6 Aug 2013	3,776
3	Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial Christina Davies et al. · The Lancet Open access	5 Dec 2012	2,067
4	Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015 Alan Stuart Coates et al. · Annals of Oncology Open access	4 May 2015	1,865
5	Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23–01): a phase 3 randomised controlled trial Viviana Enrica Galimberti et al. · The Lancet Oncology Open access	10 Mar 2013	1,247
6	Overview of the main outcomes in breast-cancer prevention trials Jack M. Cuzick, T.J. Powles, Umberto Veronesi et al. · The Lancet	2003	965
7	Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007 Aron Goldhirsch, W. C. Wood, Richard D. Gelber et al. · Annals of Oncology Open access	Jul 2007	947
8	Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial R. Charles Coombes et al. · The Lancet	Feb 2007	914
9	Adjuvant Ovarian Suppression in Premenopausal Breast Cancer Prudence A. Francis et al. · New England Journal of Medicine Open access	11 Dec 2014	736
10	Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer Prudence A. Francis et al. · New England Journal of Medicine Open access	4 Jun 2018	694
11	Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial Jack M. Cuzick, Ivana Šestak, John Forbes et al. · The Lancet Open access	12 Dec 2013	591
12	Long-Term Results of Tamoxifen Prophylaxis for Breast Cancer--96-Month Follow-up of the Randomized IBIS-I Trial Jack M. Cuzick, JF Forbes, Ivana Šestak et al. · JNCI Journal of the National Cancer Institute Open access	20 Feb 2007	536
13	Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer Charles E. Geyer et al. · Annals of Oncology Open access609 authors	10 Oct 2022	477
14	Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial Jack M. Cuzick, Ivana Šestak, Simon Cawthorn et al. · The Lancet Oncology Open access	11 Dec 2014	466
15	Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG) Bernhard C. Pestalozzi, David Zahrieh, Karen N. Price et al. · Annals of Oncology Open access	8 Apr 2006	413
16	Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up Meredith M. Regan, Patrick Neven, Anita Giobbie‐Hurder et al. · The Lancet Oncology Open access	24 Oct 2011	410
17	Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up Martine J Piccart et al. · Journal of Clinical Oncology Open access	4 Feb 2021	374
18	Quality of life in oncology practice: Prognostic value of EORTC QLQ-C30 scores in patients with advanced malignancy Alan Stuart Coates, Franz Porzsolt, David Osoba · European Journal of Cancer	Jun 1997	334
19	Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer—The Penelope-B Trial Sibylle Loibl et al. · Journal of Clinical Oncology	Apr 2021	332
20	Multicenter Phase III Randomized Trial Comparing Docetaxel and Trastuzumab With Docetaxel, Carboplatin, and Trastuzumab As First-Line Chemotherapy for Patients With HER2- Gene-Amplified Metastatic Breast Cancer (BCIRG 007 Study): Two Highly Active Therapeutic Regimens Vicente Valero, John Forbes, Mark Daniel Pegram et al. · Journal of Clinical Oncology Open access	30 Nov 2010	262
21	Use of anastrozole for breast cancer prevention (IBIS-II): long-term results of a randomised controlled trial Jack M. Cuzick, Ivana Šestak, John Forbes et al. · The Lancet Open access	12 Dec 2019	239
22	Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial Arlene Chan et al. · Clinical Breast Cancer Open access	5 Oct 2020	221
23	Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial John Forbes, Ivana Šestak, Anthony Howell et al. · The Lancet Open access	15 Dec 2015	201
24	Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial Manuela Rabaglio, Zijie Sun, Karen N. Price et al. · Annals of Oncology Open access	27 May 2009	187
25	Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials Jürg Bernhard et al. · The Lancet Oncology Open access	16 Jun 2015	179
26	Adjuvant Exemestane With Ovarian Suppression in Premenopausal Breast Cancer: Long-Term Follow-Up of the Combined TEXT and SOFT Trials Olivia Pagani et al. · Journal of Clinical Oncology Open access	15 Dec 2022	167
27	The effect of body mass index on overall and disease-free survival in node-positive breast cancer patients treated with docetaxel and doxorubicin-containing adjuvant chemotherapy: the experience of the BIG 02-98 trial Evandro de Azambuja, Worta McCaskill‐Stevens, Prudence A. Francis et al. · Breast Cancer Research and Treatment Open access	2 Sep 2009	161
28	Adjuvant Chemotherapy With Sequential or Concurrent Anthracycline and Docetaxel: Breast International Group 02 98 Randomized Trial Prudence A. Francis, John P. Crown, Angelo Di Leo et al. · JNCI Journal of the National Cancer Institute Open access	8 Jan 2008	153
29	Absolute Improvements in Freedom From Distant Recurrence to Tailor Adjuvant Endocrine Therapies for Premenopausal Women: Results From TEXT and SOFT Olivia Pagani, Prudence A. Francis, Gini F. Fleming et al. · Journal of Clinical Oncology Open access	16 Oct 2019	151
30	The Epidemiology of Breast Implant–Associated Anaplastic Large Cell Lymphoma in Australia and New Zealand Confirms the Highest Risk for Grade 4 Surface Breast Implants Mark Magnusson, Ken Beath, Rodney D. Cooter et al. · Plastic & Reconstructive Surgery	21 Feb 2019	145
31	Dynamic balanced randomization for clinical trials D. F. Signorini, Oberon K. Leung, R. John Simes et al. · Statistics in Medicine	30 Dec 1993	143
32	Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer Manuel A. R. Ferreira et al. · Nature Communications Open access318 authors	15 Apr 2019	139
33	Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial L. Mauriac, Aparna P. Keshaviah, Marc Debled et al. · Annals of Oncology Open access	15 Feb 2007	139
34	A systematic review of decision aids for patients making a decision about treatment for early breast cancer Nicholas Zdenkowski, Phyllis Noemi Butow, Stephanie Tesson et al. · The Breast Review	7 Jan 2016	137
35	Deciphering the apoptotic pathway: All roads lead to death Lisa F. Lincz · Immunology and Cell Biology	Feb 1998	127
36	Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial Marco Angelo Colleoni et al. · The Lancet Oncology Open access254 authors	17 Nov 2017	122
37	CA15-3 and alkaline phosphatase as predictors for breast cancer recurrence: a combined analysis of seven International Breast Cancer Study Group trials Aparna P. Keshaviah, Silvia Dellapasqua, Nicole Rotmensz et al. · Annals of Oncology Open access	21 Jan 2007	107
38	Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial Giuseppe Viale, MM Regan, Patrizia Dell’Orto et al. · Annals of Oncology Open access	19 Feb 2011	105
39	Neoadjuvant buparlisib plus trastuzumab and paclitaxel for women with HER2+ primary breast cancer: A randomised, double-blind, placebo-controlled phase II trial (NeoPHOEBE) Sibylle Loibl, Lorena de la Peña, Valentina Nekljudova et al. · European Journal of Cancer Open access	18 Sep 2017	104
40	First—select the target: better choice of adjuvant treatments for breast cancer patients A. Goldhirsch, Alan Stuart Coates, Richard D. Gelber et al. · Annals of Oncology Open access	27 Oct 2006	98
41	The Perceived Adjustment to Chronic Illness Scale (PACIS): a global indicator of coping for operable breast cancer patients in clinical trials Christoph Hürny, Jürg Bernhard, Marisa Bacchi et al. · Supportive Care in Cancer	Jul 1993	98
42	Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial Cristina Saura et al. · The Lancet Oncology	8 Aug 2019	97
43	Decreased expression of key tumour suppressor microRNAs is associated with lymph node metastases in triple negative breast cancer Kelly A. Avery‐Kiejda, Stephen G. Braye, Andrea Mathe et al. · BMC Cancer Open access	31 Jan 2014	93
44	POSNOC—POsitive Sentinel NOde: adjuvant therapy alone versus adjuvant therapy plus Clearance or axillary radiotherapy: a randomised controlled trial of axillary treatment in women with early-stage breast cancer who have metastases in one or two sentinel nodes Amit Goyal et al. · BMJ Open Open access	Dec 2021	92
45	Final Analysis of the Prevention of Early Menopause Study (POEMS)/SWOG Intergroup S0230 Halle C. F. Moore et al. · JNCI Journal of the National Cancer Institute Open access	12 Sep 2018	92
46	Improving decision making about clinical trial participation – a randomised controlled trial of a decision aid for women considering participation in the IBIS-II breast cancer prevention trial Ilona Juraskova, Phyllis Noemi Butow, Carissa Bonner et al. · British Journal of Cancer Open access	3 Jun 2014	90
47	Prognosis of medullary breast cancer: analysis of 13 International Breast Cancer Study Group (IBCSG) trials Jens Huober, Shari I. Gelber, Aron Goldhirsch et al. · Annals of Oncology Open access	17 Jun 2012	87
48	Adjuvant treatment of premenopausal women with endocrine-responsive early breast cancer: Design of the TEXT and SOFT trials Meredith M. Regan, Olivia Pagani, Gini F. Fleming et al. · The Breast Open access	2 Oct 2013	87
49	Telehealth in cancer care: during and beyond the COVID ‐19 pandemic Kate Burbury, Zee‐Wan Wong, Desmond Yip et al. · Internal Medicine Journal Open access	2021	83
50	Cognitive function in postmenopausal women receiving adjuvant letrozole or tamoxifen for breast cancer in the BIG 1-98 randomized trial Kelly‐Anne Phillips, Karin Ribi, Zhuoxin Sun et al. · The Breast Open access	11 Apr 2010	83

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.